Research in contextEvidence before this studyHigh Grade Serous Carcinoma is the fifth most lethal gynecological malignancy with poor overall survival rates. Early detection is paramount to reducing the lethality of the disease in later stages of carcinogenesis. Despite numerous advances in the field, the etiology of the disease and its development and origin from the Fallopian tube remains not fully understood. Our previous work suggested that C/EBPδ responds to inflammation and acute cytotoxic stresses induced by ovulation in BRCA1 mutation carriers. Moreover, C/EBPδ has been shown to be a tumour suppressor in breast cancers, but a master regulator and oncogene in glioblastoma multiforme. Its function therefore is context dependent and no studies currently have determined its role in the initiation of ovarian cancer.Added value of this studyThis study sheds light on the role of C/EBPδ in normal Fallopian tube epithelia and cancer. We show that C/EBPδ decreases cell growth and promotes a mesenchymal to epithelial transition in epithelial cells. Using in vitro assays, we show that C/EBPδ also increases the migration potential of these cells, demonstrating a dichotomous role for C/EBPδ. Together, this data show that C/EBPδ is capable of modulating downstream factors which can alter the phenotype of the cells and regulate the development of the disease.Implications of all the available evidenceOur research indicates that C/EBPδ is an important transcriptional regulator in the initiation of ovarian cancer from the Fallopian tubes. C/EBPδ enables cells to maintain an epithelial-like phenotype and decreases proliferation in normal cells. In cancer cells, C/EBPδ promotes migration, EMT/MET, cell survival through IL-6/STAT3 signals and promotes genomic stability. In toto, evidence suggests that C/EBPδ could be an attractive target for therapy in certain cancer types.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

High-grade serous ovarian cancer (HGSC) remains the most fatal gynecological malignancy and accounts for the majority of deaths due to ovarian cancer \[[@bb0005],[@bb0010]\]. Improving early detection, prevention and overall prognosis was limited by a lack of understanding of the etiology of HGSC. Now, significant data suggests the distal end of the fallopian tube is the site of origin for HGSC \[[@bb0015]\]. Detailed histopathological examination of the fallopian tube epithelium in *BRCA* mutation carriers undergoing prophylactic bilateral salpingo-oophorectomy led to the identification of precursor lesions \[[@bb0020], [@bb0025], [@bb0030]\].

A pre-neoplastic lesion called the p53 signature is the earliest mutational and genomic event described in the gradual steps of HGSC development \[[@bb0035]\]. The acquisition of somatic *TP53* mutations is followed by additional genomic alterations, cellular tufting, and loss of polarity, resulting in the development of neoplastic serous tubal intraepithelial carcinoma (STIC) \[[@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070]\]. STIC lesions share multiple genomic copy number alterations, along with mutations in tumour suppressors and oncogenes, including *TP53*, *BRCA1* and *BRCA2*, *RB1*, *STK11*, *FOXO3a*, *CCNE1*, *STATHMIN1,* and *hTERT*, which are observed prior to HGSC metastasis to the ovaries and peritoneal spread \[[@bb0040],[@bb0060],[@bb0075], [@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115]\]. In this model, cells that exfoliate from the fallopian tube into the peritoneal cavity must evade anoikis and detachment associated apoptosis before attaching to the mesothelial ovarian surface \[[@bb0120],[@bb0125]\].

The fallopian tube epithelia (FTE) undergo monthly cycles of hormonally driven proliferation and differentiation. In a previous study, we identified CCAAT/enhancer binding protein delta (C/EBPδ*, CEBPD*), to be transcriptionally upregulated in the FTE of *BRCA1* mutation carriers and in the post-ovulatory (luteal) phase of the ovarian cycle, a process linked to cytotoxic stress \[[@bb0130]\]. *C/EBPδ* is located on chromosome 8q11.21 and belongs to the superfamily of highly conserved basic-leucine zipper (b-ZIP) domain transcriptional factors \[[@bb0135]\]. It has multiple functions related to inflammation, cell cycle regulation, differentiation, and metabolism \[[@bb0130], [@bb0135], [@bb0140], [@bb0145]\]. Although C/EBPδ overexpression promotes glioblastoma progression and is associated with poor progression in pancreatic and urothelial cancers \[[@bb0150],[@bb0155]\], its overexpression in breast, prostate, and myeloid cancers, inhibits growth and promotes differentiation \[[@bb0160], [@bb0165], [@bb0170]\]. Furthermore, low expression of C/EBPδ was reported in cervical, hepatocellular carcinoma \[[@bb0175],[@bb0180]\], breast \[[@bb0185]\], prostate cancer \[[@bb0190]\], and leukemia \[[@bb0160]\]. C/EBPδ\'s pro-oncogenic/tumour suppressive function is cell type and context dependent \[[@bb0150],[@bb0175],[@bb0195], [@bb0200], [@bb0205]\]. Little is known about the role of C/EBPδ in the development of HGSC. The objectives of this study were to explore expression of C/EBPδ in HGSC tumours as well as precursor lesions and determine the effects of C/EBPδ on FTE cancer cell growth and migration.

2. Material and methods {#s0025}
=======================

2.1. Case collection {#s0030}
--------------------

The University Health Network Research Ethics Board approved the study protocol for collection of tissue and clinical information for all patients. Each patient provided written informed consent allowing for the collection and use of tissue for research purposes. H&E sections of high-grade serous carcinoma, borderline and low-grade serous carcinoma were reviewed by a gynecological pathologist (P.S.) prior to use in the study. Diagnosis of each case was retrieved from the UHN ovarian tissue bank prior to review. To validate immunohistochemical protein expression of samples, whole sections of tissue were cut from formalin fixed paraffin embedded tissue and analyzed as in our previous publication \[[@bb0040],[@bb0075],[@bb0210]\]. A previously published cohort (n = 15) of serous tubal intraepithelial carcinoma (STIC) cases using Abcam morphological and immunohistological features including cellular crowding, loss of nuclear polarity and presence of p53 and Ki67, from women having adnexal high-grade serous carcinoma \[[@bb0040],[@bb0075],[@bb0215]\].

2.2. Immunohistochemistry {#s0035}
-------------------------

Immunohistochemistry was performed using standard procedures as previously described \[[@bb0220]\] with the following modifications. The following antibodies were used at these dilutions: Ki67 (Lab Vision, Thermo Scientific, Waltham, Massachusetts, USA) 1/1000; p53 (Novocastra, Leica, Wetzlar, Germany) 1/200; C/EBPδ 1/200 (sc-636) (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA); E-cadherin 1/100 (AB15148) (Abcam, Cambridge, United Kingdom); Vimentin 1/100 (5741S) (Cell Signaling Technology, Danvers, Massachusetts, USA). Appropriate negative and positive controls were performed to determine specificity of antibodies. Stained slides were scanned using the ScanScope XT slide scanner (Aperio Technologies, Inc., Leica) to create digital images at 40× magnification which were then quantified for intensity and percentage of cells staining using a nuclear algorithm as previously described (Spectrum Plus, Image Analysis Toolbox, TMALab II, Aperio, Inc.) \[[@bb0130],[@bb0210]\]. Intensity levels were based on an absorption range scale of 0 to 255 (0 = black; 255 = white). Weak Intensity Staining (1+) ranged from 200 to 215; medium intensity staining (2+) from 180 to 200; and strong intensity staining (3+) from 0 to 180. Intensity levels +2 and + 3 were combined to create a composite score for the percent positive nuclei present in each case. Images were annotated to include only epithelium while excluding stroma.

2.3. Immunofluorescence {#s0040}
-----------------------

Cells were grown in 6-well plates (Falcon) coated with collagen IV and fixed with 4% PFA for 5 min, permeabilized with 0.3% Triton-X/PBS then blocked with 5% goat serum (Gibco, Life technologies) in PBS. Primary antibodies: C/EBPδ (SC-636), CK18 (M701029) (Dako, Agilent Technologies, Santa Clara, California, United States), Pax8 (10336-1-AP) (ProteinTech, Rosemont, IL, USA), E-cadherin (AB15148) (Abcam), Vimentin (5741S) (Cell Signaling), were applied overnight at 4 °C. Primary antibody was removed by washing samples with 1× PBS three times and was incubated with appropriate fluorophore-labeled secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and Vectashield (H-1200, Vector Laboratories, Burlingame, CA, USA) in a dark area for 45 min. Cells were again washed for three times with 1× PBS and was mounted onto a coverslip and dried in the dark for 10 min. Samples were visualized using a Leica Axioimager (Leica).

2.4. Fallopian tube epithelia tissue cultures {#s0045}
---------------------------------------------

Surgical samples were obtained from the University Health Network with patient consent and Research Board Ethics Approval. In brief, fimbriae were collected after prophylactic hysterectomy or salpingo-oophorectomy and incubated for 4-16 h at 37 °C in pronase and subsequently cultured as previously described \[[@bb0040]\]. Three independent patient derived fallopian tubes were used in this study: 71-FTE, age 50; 57-FTE, age 29; and 19-FTE, age 48. Cells were immortalized via infection with a lentiviral dominant negative TP53 (R175H) vector and retroviruses human telomerase (hTERT) \[[@bb0040]\]. Cells were infected with a lenti-viral C/EBPδ overexpression construct 24-48 h after cells reached 70% confluence. Each plate was grown till 70% confluence and harvested for different molecular assays. For biological replicates, all molecular analyses of cell lines for RNA and protein extraction were performed from the cell population. That is, at time of collection, cells were divided into two pellets. Additionally, for FACS and immunofluorescence, the same population of cells were pelleted for RNA and protein assays.

2.5. Cell lines {#s0050}
---------------

SKOV3, OVCAR3, MCF7, MDA231, T47D were obtained from the ATCC (Manassa, Virginia, USA). SKOV3 (ATCC-HBT-77) was grown in McCOY\'s 5a (Life technologies, Carlsbad, California, USA) supplemented with 10% fetal bovine serum (FBS, Wisent technologies, St-Bruno, Quebec

Canada). MCF7 (ATCC-HTB-22) and MDA231 (ATCC-HTB-26) cells were grown in DMEM/F12 (Life technologies), supplemented with 10% FBS. T47D (ATCC-HTB-133) and OVCAR3 (HTB-161) cells were grown in RPMI-1640 (Life technologies), supplemented with 10% and 20% FBS, respectively. Culture method was followed as described by ATCC for each cell line. Kuramochi (JCRB No. JCRB0098) and OVSAHO (JCRB No. JCRB1046) cells were obtained from JCRB (Japanese Collection of Research Bioresources) Cell Bank and Sekisui Xenotech LLC (Cambridge, Kansas City, USA). Cells were grown in RPMI-1640 (Life technologies) supplemented with 10% FBS.

2.6. Virus production and infection {#s0055}
-----------------------------------

HEK-293T cells were seeded at a density of 1.0 × 10\^6 cells per plate in a 6 cm tissue culture dish overnight with low antibiotic growth media (DMEM +10% FBS). Cells were incubated until 70% confluence was achieved. A mixture of three transfection plasmids were produced by combining 2 μg pMDG.2 (Addgene \#12259) (Addgene, Watertown, Massachusetts, USA); 4 μg of pCMV delta R8.2 (Addgene \#12263) and 5 μg of vector (pCDH-CMV-MCS-EF1-GFP empty, pCDH-CMV-MCS-EF1-GFP-C/EBPδ - C/EBPδ-OE). As per manufacturer\'s protocol, GenJet DNA In-vitro Transfection reagent (Ver. II) (SignaGen Laboratories, Rockville, MD, USA) was used as the transfection reagent. Reagents were added to each plate drop-wise and was incubated overnight (16 h, 37 °C, 5% CO~2~). Next day, media was subsequently removed and replaced with high BSA growth media and again incubated for 24 h. Supernatant was then collected and passed through a 0.45 μm filter and snap frozen and stored at −80 °C until required for use. A second round of collection was performed 72 h after virus transfection and was also filtered and stored at −80 °C.

2.7. Protein isolation, western blot and antibodies {#s0060}
---------------------------------------------------

Cell samples were washed with 1× PBS and trypsinized using 0.25% trypsin dissociation reagent (Life technologies) for 5 min at 37 °C. Trypsin neutralizing solution (TNS) was added to samples and was spun at 1000 rpm for 5 min. Supernatant was aspirated, and samples were placed on ice before lysing. Cells were lysed with NP40 buffer (Life technologies) and protease inhibitor cocktail (Thermo Scientific). Samples were incubated for 15 min on ice and subsequently clarified by centrifugation (14,000 rpm for 30 min). The supernatant was collected and quantified using BioRad DC Protein Assay (BioRad Laboratories, Hercules, California, United States). Samples were re-suspended in 4× LDS sample buffer (Life technologies), boiled, and 30 μg of protein was resolved by SDS-Page 4--12% Bis-tris Gels (Novex, Life technologies). Protein samples were transferred to BioRad PVDF membrane and were blocked with 5% milk powder dissolved in 1× TBS-T for 1 h or overnight. Primary antibodies were diluted in blocking buffer (5% skimmed milk, Nestle, Vevey, Switzerland) and incubated with membranes overnight at 4 °C. Membranes were washed for 10 min, three times and probed with secondary antibody, washed three times for 15 min using 1× TBS-T, and developed using ECL Prime western blotting detection reagent (GE Healthcare Life Sciences, Pittsburgh, PA, USA). Each membrane was imaged using BioRad ChemiDoc and images analyzed using BioRad Image Lab software (BioRad ImageLab v5.2.1, build 11). The following antibodies were used in western blots: C/EBPδ (Santa Cruz, SC-636, 1/200) (In some instances, this polyclonal antibody has produced double bands as seen in [Fig. 4](#f0020){ref-type="fig"}d), B-actin (Sigma, A2228, 1/1000) (Sigma-Aldrich, St. Louis, Missouri, USA), P53 (Santa Cruz; sc-126, 1/500), PAX8 (ProteinTech, 10,336-1-AP, 1/1000), Snail (Cell Signaling, 3895S, 1/500), Slug (Cell Signaling, 9585S, 1/500) Vimentin (Cell Signaling, 5741S, 1/500), E-cadherin (Abcam, AB15148 1/500), E-cadherin (Cell Signaling, 24E10,\#3195, 1/500), N-cadherin (SantaCruz, sc-7939, 1/500), SIP1 (Santa Cruz, sc-48,789, 1/200), Twist (Santa cruz, sc-81,417, 1/500), and goat HRP-IgG (anti-mouse or anti-rabbit) (Santa Cruz, 1:10,000). Western Blot quantification for C/EBPδ protein was carried out across each cell line using ImageLab imaging software (BioRad ImageLab, v5.2.1, build 11)([Supplementary Figs. S2](#f0040){ref-type="graphic"}e and [S5](#f0055){ref-type="graphic"}d). Raw values, measured in units of intensity (INT) were used to graph protein expression.

2.8. Cloning strategy {#s0065}
---------------------

Overexpression vectors were constructed using pCDH-CMV-MCS-EF1-GFP cloning/expression vector (System Biosciences, Palo Alto, CA, USA). C/EBPδ insert was cut out of a PCR4 TOPO cloning vector (Invitrogen, Carlsbad, California, USA) using *Eco*RI (New England Biolabs (NEB), Ipswich, Massachusetts, USA). The cDNA was then ligated into pCDH-CMV-MCS-EF1-GFP using Takara ligation Kit (Clontech, Mountain View, California, USA) and was confirmed in the expression vector by DNA sequencing at The Centre for Applied Genomics (SickKids, Toronto, Ontario, Canada). Lentivirus was produced using HEK-293 T cells (Clontech) and the overexpression vector was confirmed in the cells by GFP fluorescence and western blot ([Fig. 2](#f0010){ref-type="fig"}a--b, [Supplementary Fig. S4](#f0050){ref-type="graphic"}a).

2.9. Fluorescence activated cell sorting (FACS) {#s0070}
-----------------------------------------------

For cell cycle regulation assessment, cells were washed in 1× PBS and 10 μM BrdU-APC was added to cells in a dark environment. Plates with BrdU were then incubated at 37 °C for 4 h. Cells were then washed twice with ice cold PBS, trypsinized with 0.25% trypsin dissociation reagent and neutralized for counting. Nuclei preparation and staining was performed by adding 0.08% Pepsin and 2 N HCl and IFA/0.5%, Tween20 (Sigma). Samples were incubated in the dark and 100 μl anti-BrdU-APC was added while samples were incubated on ice. 5 μg/ml of propidium iodide (PI) was added to cells and incubated on ice for 15 min. Flow cytometry was carried out on BD FACS Calibur (BD biosciences, San Jose, CA, USA). Data was analyzed using FlowJo v10 (Flowjo LLC, Ashland, OR, USA). Cell surface staining was performed on single cell suspension. EpCAM-PE (Life technologies, VU-1D9) and CD49f-APC (FAB13501A) (R&D Biosystems, Minneapolis, Minnesota, USA) was added to the cell suspension and incubated in the dark for 40-60 min. Cells were then washed and centrifuged at 400 *g* for 5 min at room temperature and subsequently vortexed to dissociate pellet. Stained cells were re-suspended in staining buffer and flow cytometry performed on BD Calibur flow cytometer (BD biosciences).

2.10. Soft agar assay {#s0075}
---------------------

Base agar (1% agarose Difco Agar Noble, BD biosciences) was added to 6-well plates and allowed to solidify for 5 min. Top agarose layer was made by combining 0.7% agarose with media. 5000 cells were added to the mixture and plated on 6-well plate. Cells were kept in an incubator at 37 °C for 14 days. Cells were fed twice a week. After 14 days, each plate well was stained with 0.5 ml of crystal violet (0.005%) for approximately 1 h. Plates were then imaged using a dissecting microscope and camera setup (Leica). Images were imported into ImageJ (v1.47), National Institute of Health, Bethesda, Maryland, USA) and analyzed in GraphPad (GraphPad, La Jolla California USA, Version 8.0.1 (244) using an unpaired *t*-test (*p* \< 0.05).

2.11. Quantitative PCR {#s0080}
----------------------

RNA was isolated from FTE cells lysed with Trizol reagent (Invitrogen). 1 μg of total RNA was reverse-transcribed using qScript cDNA SuperMix (Quanta Biosciences, Beverly, MA, USA). Real-time quantitative PCR (RT-qPCR) was performed using PerfeCTa Sybr Green FastMix, Rox (Quanta Biosciences) according to the manufacturer\'s protocol using the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, California, USA). The target CT values were normalized to b-actin. The N-fold differential expression was assessed using the 2-^(ΔΔCT)^ method to determine differences between treated cells and controls. Primer sequences were obtained from PrimerBank \[[@bb0225],[@bb0230]\]. qRT-PCR as mean ± SEM. An unpaired *t*-test with *n* = 3, *p* ≤ 0.05 was determined in GraphPad Image Analysis Software, unless noted otherwise in text. *N* = 3 represents 3 independent experiments with 3 technical replicates within each experiment.

2.12. miRNA assay {#s0085}
-----------------

FTE cells were harvested from 6 cm plates and RNA was isolated using miRNAeasy micro kit (Qiagen, Hilden, Germany). Quantity and quality of total RNA was analyzed using Nanodrop (Thermo Scientific). RNA was reverse transcribed into cDNA using miScript II RT kit (Qiagen). cDNA was then processed using miScript SYBR Green PCR kit (Qiagen) and was run on miScript miRNA PCR Array Human Ovarian Cancer plates (Qiagen, MIHS-110ZE-4, 384-well plate). PCR plates were read on the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). Results were outputted with 2^-\ ΔCt^ values for each gene in each treatment group compared to the control group (n = 3). Qiagen software was used to analyze results and student\'s *t*-test provided statistically significant miRNA (*p* \< 0.05).

2.13. Wound-healing assay {#s0090}
-------------------------

63857 p53DN-hTERT (57-FTE), 3619 p53DN-hTERT (19-FTE) cells were seeded in 96-well plates (Essen ImageLock) and grown to confluence. Scratch wounds were generated using the 96-pin WoundMaker (Essen BioScience, Ann Arbor, MI, USA) and wells were gently washed with 1× PBS to remove non-adherent cells. Cells were imaged using the INCUCYTE™ Kinetic Imaging System (Essen BioScience) and wound width (μm) was determined using the INCUCYTE™ cell migration software module.

2.14. Migration assay {#s0095}
---------------------

MCF7 cells and FTE cells were seeded onto Costar Transwell migration assay (Corning Costar 3472) (Corning Inc., Corning, New York, USA) at a density of 50,000 cells. Plated cells were initially grown in serum free media for 24 h. After trypsinization using Trypsin (EDTA 0.25%) (Life Technologies), cells were counted and plated onto the Transwell migration assay which was then placed in DMEM/F12 + 10% FBS for 12 h. Transwell\'s were then removed from the assay and washed with PBS and H~2~O to remove unbound cells. 1% Crystal Violet +2% ethanol was added to the Transwell and allowed to incubate at room temperature for 15 min at which point the wells were rinsed with H~2~O and dried. Each well was imaged using an inverted microscope (Leica) and cells were counted in ImageJ (ImageJ labs). Results were analyzed with an unpaired *t*-test (*p* \< 0.05) and graphed using GraphPad graphing software (GraphPad, La Jolla California USA, Version 8.0.1 (244)).

2.15. Proliferation assay {#s0100}
-------------------------

For a proliferation assay, 3.0 × 10^4^ cells were seeded onto a 6-well plate (Falcon, Corning Inc.) and plated with 2 ml of fresh media. Cells were counted every 1--3 days using CyQuant Direct Proliferation Assay kit (Life technologies). An inverted plate reader (Flexstation 3) (Molecular Devices, San Jose, California, USA) was used to quantify the amount of fluorescence emitted by live cells and provide a count of live cells present. Softmax Pro software (Molecular Devices) was to measure fluorescence and results were analyzed using an unpaired *t*-test in GraphPad (*p* \< 0.05).

2.16. Statistical analysis {#s0105}
--------------------------

Statistical analysis was performed using GraphPad Prism Software (GraphPad, Version 8.0.1 (244)). The Log-rank test was used in Kaplan-Meier, Mantel-Cox regression analysis to compare *C/EBPδ* expression on overall survival and progression free survival. MicroRNA analysis was performed using Qiagen SaBiosciences miScript miRNA PCR Array Data Analysis Software (Qiagen, v1.1). Values are expressed as means ± SEM and were experiments were performed three times. Unpaired *t*-tests were performed to determine statistical significance, unless otherwise noted. A value with *p* \< 0.05 was considered to be statistically significant.

3. Results {#s0110}
==========

3.1. C/EBPδ protein expression across two distinct histoypes (low grade serous and high grade serous tumours) varies {#s0115}
--------------------------------------------------------------------------------------------------------------------

We previously reported higher expression levels of C/EBPδ at the mRNA and protein levels in the luteal phase of the normal fallopian tube epithelia \[[@bb0130]\]. To investigate C/EBPδ protein expression levels across serous ovarian cancer histotypes, immunohistochemistry was performed on a cohort of 366 high grade serous carcinoma (HGSC) and 26 low-grade serous carcinoma (LGSC) on five independent tissue microarrays (TMAs). The C/EBPδ protein is localized primarily to the nucleus of the cell with some diffuse cytoplasmic staining. Each core was annotated to include epithelia and exclude stroma. Mean intensity and percent positivity using a nuclear stain algorithm was reported based on the following histoscores: no expression (0); low (+1); medium (+2), and high (+3) ([Fig. 1](#f0005){ref-type="fig"}a). In FTE, C/EBPδ protein is expressed in the nuclei of secretory and ciliated cells. Seventy-six per cent (76.5%, 280/366) of HGSC cases had low or attenuated (histoscore of 0/+1) C/EBPδ protein expression whereas 24% (86/366) had a medium to high expression (histoscore of +2/+3). Seventy-six per cent (76.9%, 20/26) of LGSC cases had medium to high expression compared to 23% (6/26) with low C/EBPδ expression. Overall, HGSC had 2-fold lower C/EBPδ protein expression relative to LGSC (*p* = 0.0004) ([Fig. 1](#f0005){ref-type="fig"}b).Fig. 1C/EBPδ is differentially expressed across two distinct serous histotypes, HGSC and LGSC. a. Representative IHC nuclear staining of C/EBPδ showing examples of HGSC and LGSC expressing low and high C/EBPδ expression, respectively. Percentage of C/EBPδ staining was scored from 0 (low) to 3 (high). b. Histogram shows C/EBPδ expression levels stratified by scores across a cohort of HGSC (n = 366) and LGSC (n = 26). c. Dot plot of representative samples shows decreasing C/EBPδ IHC staining across normal FTE (n = 13), STIC (n = 13) and HGSC (n = 12). C/EBPδ expression differs significantly between normal FTE and HGSC tumour samples. d. Representative IHC staining of p53, Ki67 and C/EBPδ in histologically normal fallopian tube epithelia, STIC and HGSC, respectively. e. Quantification of both C/EBPδ and Ki67 levels in FTE (n = 13), STIC (n = 12), and HGSC cases (n = 12) demonstrated an inverse relationship between C/EBPδ and Ki67 in normal (*p* = 0.01) and HGSC cases (*p* = 0.0001). Data are represented as mean +/− SEM and *p*-values are calculated using student *t*-tests, two-tailed (\**p* \< 0.05; \*\*\*\* *p* \< 0.0001).Fig. 1

In the TCGA ovarian cancer dataset \[[@bb0090]\], 2.5% (8/316) of HGSC cases had an amplification and 3.1% (10/316) had a shallow deletion of *C/EBPδ* with few cases (\<10%) having the mRNA downregulated (<http://bit.ly/2DW9QPa>).

3.2. Reduced C/EBPδ expression levels in STIC lesions reflect early changes observed in HGSC {#s0120}
--------------------------------------------------------------------------------------------

Since C/EBPδ protein levels are higher in normal FTE and differentially expressed in HGSC, we assessed C/EBPδ protein expression in a small cohort of matched normal FTE, STIC and HGSC (n = 13). Our data revealed that 53.8% (7/13) of normal fallopian tube cases had higher C/EBPδ protein expression levels (+2/+3 expression) compared to other STIC\'s and HGSC, whereas in 46% (6/13) of cases, C/EBPδ protein expression was maintained between FTE and STIC. In normal FTE, high C/EBPδ protein expression was associated with low proliferation as determined by Ki67 expression (*p* = 0.02). In STIC, however, C/EBPδ expression was slightly lower than in normal FTE, while Ki67 expression increased relative to normal FTE (*p* = 0.08) and HGSCs. There were fewer C/EBPδ expressing cells in HGSC relative to highly proliferative (Ki67^+^) and p53 expressing cells (*p* \< 0.0001) ([Fig. 1](#f0005){ref-type="fig"}c-e). Overall, C/EBPδ expression was inversely related to proliferation during the transition from normal FTE, to STIC and subsequently HGSC. Given the results and the known role of C/EBPδ in cell cycle control, we sought to determine whether overexpression of C/EBPδ would regulate FTE and cancer cell growth.

3.3. Overexpression of C/EBPδ decreases proliferation in premalignant fallopian tube epithelia {#s0125}
----------------------------------------------------------------------------------------------

### 3.3.1. Fallopian tube epithelia {#s0130}

To model p53 signatures in vitro, FTE cell lines with a p53-R175H dominant negative mutation (p53DN) and human telomerase (hTERT) over-expression were generated ([Fig. 2](#f0010){ref-type="fig"}a) \[[@bb0040]\]. As expected from immunohistochemical data, proliferating p53DN FTE cell lines had low levels of endogenous C/EBPδ protein ([Fig. 2](#f0010){ref-type="fig"}b--c). A C/EBPδ gain-of-function model was generated with a lentivirus based *pCDH-CMV-GFP-PURO* expression vector, to examine its effects on proliferation of FTE cells. Three independent FTE cell lines were transfected with either empty vector (FTE-Ctrl) or C/EBPδ cDNA vector (FTE-C/EBPδ-OE) to generate stable lines ([Fig. 2](#f0010){ref-type="fig"}a-b, [Supplementary Figs. S1](#f0035){ref-type="graphic"}a, b and [S2](#f0040){ref-type="graphic"}a). C/EBPδ protein abundance was confirmed by immunofluorescence (localized to the nucleus) and by western blot analyses ([Fig. 2](#f0010){ref-type="fig"}b-c, [Supplementary Figs. S1](#f0035){ref-type="graphic"}a and [S2](#f0040){ref-type="graphic"}a). To examine the role of C/EBPδ in cell cycle regulation, cell cycle analysis and growth kinetics were performed on FTE-Ctrl and FTE-C/EBPδ-OE cell lines. Over-expressing C/EBPδ protein reduced cell growth compared to controls, as measured by population doubling (PD) over time (19-FTE-C/EBPδ-OE versus control, 7.1-fold, *p* = 0.04; 57-FTE-C/EBPδ-OE vs control, 14.9-fold, *p* = 0.01; each in triplicate) ([Fig. 2](#f0010){ref-type="fig"}D, [Supplementary Fig. S2](#f0040){ref-type="graphic"}b). Cell cycle analysis by BrdU/propidium iodide incorporation and flow cytometry in FTE cells demonstrated a propensity for C/EBPδ overexpressing cells to accumulate in the G1 phase of the cell cycle compared to FTE-Ctrl cells (*p* = 0.0019) ([Fig. 2](#f0010){ref-type="fig"}e). C/EBPδ is known to interact with *CCND1* and promotes STAT3 induced G0 cell cycle arrest \[[@bb0235],[@bb0240]\]. In addition, overexpression of C/EBPδ decreased anchorage independent growth of FTE cells compared to control cells (19-FTE-p53DN-hTERT, 1.97-fold, *p* = 0.0009; 57-FTE-p53DN-hTERT, 1.41-fold, *p* = 0.07) ([Fig. 2](#f0010){ref-type="fig"}f), but increased colony formation in one cell line ([Supplementary Fig. S2](#f0040){ref-type="graphic"}c). Overall, the results are consistent with decreased growth rates in 2D and 3D assays. The data show that C/EBPδ overexpression is sufficient to inhibit proliferation in FTE cells likely at the G1/S phase of the cell cycle.

### 3.3.2. Breast and ovarian cancer cell lines {#s0135}

To determine C/EBPδ mRNA basal expression levels across ovarian (n = 42) and breast cancer (n = 54) cell lines, we used publically available RNA-sequencing data from Medrano et al. \[[@bb0245]\] The data uniformly showed higher C/EBPδ mRNA levels were associated with lower proliferation rates across breast and ovarian cancer cell lines ([Fig. 3](#f0015){ref-type="fig"}a-b). Pearson correlations showed an inverse correlation between C/EBPδ and MIB1 (Ki67) in ovarian cancer cell lines, but this did not reach significance (*r* = −0.183, *p* = 0.244). A pearson correlation was also performed for all breast cancer cell lines (*r* = 0.2502, *p* = 0.068). Similarly, C/EBPδ protein expression levels in chemotherapy naive HGSC tissue by western blot analyses is low, consistent with immunohistochemical data of formalin fixed tissue ([Fig. 3](#f0015){ref-type="fig"}c). To further investigate the biological consequences of C/EBPδ protein expression in cancer cell lines, we used three breast cancer cell lines (MCF7, T47D, MDA231), and three ovarian cancer cell lines (SKOV3, Kuramochi, OVSAHO). MCF7 and T47D have wildtype p53 whereas MDA231 has a p53 mutation, and SKOV3 is p53-null \[[@bb0250], [@bb0255], [@bb0260]\]. C/EBPδ is expressed in estrogen receptor positive cancer cell lines, including MCF7 (highest), T47D, and SKOV3 with no/low expression in estrogen receptor negative MDA-231 ([Fig. 3](#f0015){ref-type="fig"}d). Across Kuramochi and OVSAHO cell lines, low levels of C/EBPδ were detected ([Fig. 3](#f0015){ref-type="fig"}e). Both Kuramochi and OVSAHO expressed Vimentin and E-cadherin, although only OVSAHO expressed CK7 ([Fig. 3](#f0015){ref-type="fig"}e).Fig. 2Overexpression of C/EBPδ reduces cell proliferation. a. In vitro model of C/EBPδ overexpression in premalignant fallopian tube epithelia. Fallopian tube epithelial cells have a limited life span in vitro*.* To generate premalignant cells, FTE were infected with lentivirus containing p53 dominant negative mutation (p53DN^R175H^). Cells with p53DN^R175H^ were selected and subsequently immortalized using htert. FTE-p53DN-htert cells were then infected with either control vector or C/EBPδ. b. Phase contrast microscopy images of a FTE cell line, showing control cells (19-FTE-p53DN-hTERT-Ctrl) and C/EBPδ overxpressing cells (19-FTE-p53DN-hTERT-C/EBPδ-OE) with corresponding images of GFP expression (green) as a marker of successfully infected cells, and C/EBPδ expression (red) in the nucleus (blue). c. Confirmation of C/EBPδ protein expression by western blot in two FTE cell lines, 19-FTE and 57-FTE. PAX8 is a fallopian tube epithelial marker. d. Cell growth measured as population doublings across days in two cell lines, 19-FTE and 57-FTE. C/EBPδ overexpression significantly reduced growth in premalignant FTE. e. To determine cell cycle distribution, BrdU incorporation, and DNA content were analyzed by flow cytometry (n = 3). Representative plot showing percentage distribution of cells across cell cycle control verses C/EBPδ overexpressing cells using two cell lines, 19-FTE and 57-FTE. Statistical significance was set at *p* \< 0.05. C/EBPδ overexpression inhibited proliferation by accumulating cells in G1 phase of the cell cycle f. Anchorage independent growth assays (soft agar assays) performed on FTE-Ctrl and FTE-C/EBPδ-OE cells (n = 3). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 2Fig. 3C/EBPδ mRNA expression levels show an inverse correlation with proliferation marker and protein expression varies in HGSC samples. a. mRNA expression levels measured as fragment per kilobase per million reads (FPKM) of C/EBPδ and MIB1 (Ki67) across a panel of 42 ovarian cancer cell lines shows an inverse correlation between C/EBPδ and MIB1 mRNA expression levels. Pearson correlation comparing all ovarian cancer cell lines was performed. b. Similarly, C/EBPδ and MIB1 mRNA expression levels were analyzed across a panel of 54 breast cancer cell lines showing higher levels of C/EBPδ were associated with lower levels of MIB1 expression. mRNA expression levels are displayed as FPKM. A pearson correlation was performed between C/EBPδ and MIB1. c. Western blot analysis of C/EBPδ expression across six HGSC tumour samples. B-actin is used as a loading control. d. Western blot analysis of C/EBPδ expression across three breast cancer cell lines, MCF7, T47D, and MDA231. e. Western blot analysis of basal C/EBPδ protein expression, epithelial, and mesenchymal markers across several ovarian cancer cell lines.Fig. 3Fig. 4CEBPD overexpression promotes an epithelial cell phenotype with migratory potential. a. Representative IHC staining of C/EBPδ, E-cadherin and Vimentin in fallopian tube epithelia from the luteal and follicular phases of the menstrual cycle. b. Quantification of C/EBPδ, E-cadherin and Vimentin protein expression in 21 fallopian tube epithelia cases. c. Macroscopic images were taken using bright field light microscopy of two FTE cell models, 57-FTE and 19-FTE showing control verses C/EBPδ overexpressing cells. Black arrows indicate elongations from filopodia in C/EBPδ overexpressing cells. Images were taken at 20× magnification. d. In vitro analysis of 57-FTE and 19-FTE using western blots showing C/EBPδ, E-cadherin, Vimentin, N-cadherin expression relative to control cells. B-actin is used as a loading control. e. A wound healing assay was performed on 57-FTE and 19-FTE cell lines to demonstrate migration potential (n = 3). Wound width (μm) was measured against time of experiment (measured in hours).Fig. 4Fig. 5C/EBPδ overexpression shows differential expression of epithelial and mesenchymal markers at the protein and mRNA level. a. A quantitative PCR (qPCR) measured the relative mRNA expression levels of C/EBPδ, and EMT/MET markers, including Snail, Slug, Zeb1, Zeb2 in two FTE cell lines overxpresing C/EBPδ verses control cells. b. A western blot analysis of EMT/MET protein markers perfomed on 57-FTE and 19-FTE overexpressing C/EBPδ compared to control cells. c. A qPCR of miRNA was performed on both 57-FTE and 19-FTE cells showing the fold change in various miRNAs in cells overexpressing C/EBPδ compared to control cells. Upregulated miRNA (Red) and downregulated (Green) were identified (*p* \< 0.05, n = 3). Data are represented as mean +/− SEM and *p*-values are calculated using Student *t*-tests, two-tailed, and a 2-way ANOVA. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 5Fig. 6C/EBPδ increases E-cadherin expression in cancer cell lines. a. Representative macroscopic images of SKOV3 cell line overexpressing C/EBPδ compared to control, taken using bright field light microscopy at 20× magnification. b. Western blot analysis of C/EBPδ, mesenchymal markers Vimentin and N-cadherin, epithelial markers E-cadherin and Pax8, EMT/MET markers, including Zeb1, Zeb2, as well as ERα in SKOV3 cells overexpressing C/EBPδ compared to controls. c. Growth curve of SKOV3 cells expressing C/EBPδ relative to control cells with no C/EBPδ. d. Migration assay of SKOV3 cells with C/EBPδ-OE relative to control cells. e. Bright Field microscopy images of Kuramochi and OVSAHO expressing C/EBPδ show differences in cellular phenotype at 10× magnification. f. Cell proliferation assays of Kuramochi and OVSAHO with C/EBPδ-OE measured in fluorescence units (*p* \< 0.05, n = 3) g. Western blot analysis showing expression of C/EBPδ, E-cadherin, and Vimentin. h. Soft agar colony assay performed on Kuramochi and OVSAHO cells show a decrease in colony formation of Kuramochi cells expressing C/EBPδ (n = 3). i. A transwell migration assay shows increased migration in Kuramochi and OVSAHO cells expressing C/EBPδ (n = 3). j. A proposed pathway demonstrating the role of C/EBPδ in the EMT/MET in the context of fallopian tube epithelia. k. A model showing the role of C/EBPδ in the development of HGSC. Data are represented as mean +/− SEM and p-values are calculated using unpaired t-tests, two-tailed (\**p* \< 0.05; \*\*\* *p* \< 0.001).Fig. 6

3.4. C/EBPδ expression is associated with a MET and migratory potential in FTE {#s0140}
------------------------------------------------------------------------------

Epithelial to mesenchymal transition (EMT) has a fundamental role in cancer metastasis; restoration of the mesenchymal to epithelial transition (MET) program should efficiently slow dissemination of tumour cells \[[@bb0265]\]. Epithelial cells within fallopian tube undergo morphological changes during the menstrual cycle, evident under light microscopy \[[@bb0270],[@bb0275]\]. The FTE are characteristically pseudo-stratified epithelia consisting of cuboidal and columnar epithelial cells of secretory and ciliated cells. During the pre-ovulatory (follicular) phase there is an increase in proliferation \[[@bb0215]\]. At ovulation, the secretory cells reach peak activity and secrete their nutritive contents into the lumen of the tube, then reduce in height to allow ciliated cells to move secretions by the beating of their cilia. Subsequently, in the post-ovulatory (luteal) phase, both cell types reduce in height and there is partial deciliation \[[@bb0280]\]. C/EBPδ protein expression in the mouse ovary was previously reported to be mediated by the luteinizing hormone (LH) \[[@bb0285]\] and both mRNA and protein levels are higher in FTE in the luteal phase of the ovarian cycle \[[@bb0130]\]. Using a TMA of FTE (n = 52) \[[@bb0130],[@bb0215]\] annotated with *BRCA1* mutation and ovarian cycle status, we assessed expression of both Vimentin and E-cadherin by IHC and image analysis ([Fig. 4](#f0020){ref-type="fig"}a). Concurrent TMA slides were stained for all three proteins. In general, C/EBPδ basal protein expression was low. Interestingly, in the FTE luteal cases, where C/EBPδ expression was higher, we saw a downward shift in Vimentin^+^ expressing FTE cells (90.2% in the follicular phase to 68.5% in the luteal phase, *p* = 0.33). No significant changes in E-cadherin were observed (91.0% in follicular phase to 88.9% in luteal phase, *p* = 0.51) ([Fig. 4](#f0020){ref-type="fig"}a-b). In vitro, FTE with a p53 dominant negative mutation and hTERT retain a mesenchymal phenotype which is characterized by Vimentin protein expression as observed in FTE in vivo ([Fig. 4](#f0020){ref-type="fig"}d, [Supplementary Fig. S2](#f0040){ref-type="graphic"}a). FTE overexpressing C/EBPδ showed a distinctive epithelial-like phenotype with well-defined sheets of adhering cells compared to control cells which had more elongated mesenchymal shape ([Fig. 4](#f0020){ref-type="fig"}c). Western blot analyses demonstrated a decrease in Vimentin and increase in E-cadherin protein expression in FTE overexpressing C/EBPδ compared to controls ([Fig. 4](#f0020){ref-type="fig"}d, [Supplementary Fig. S2](#f0040){ref-type="graphic"}a, e). This data suggested a role for C/EBPδ in regulating cellular phenotypes and possibly cell differentiation. Overexpression of C/EBPδ in FTE significantly increased migration compared to control cells (57-FTE, 2.0-fold, *p* \< 0.01, and 19-FTE, 1.6-fold, *p* \< 0.01) ([Fig. 4](#f0020){ref-type="fig"}e, [Supplementary Fig. S1](#f0035){ref-type="graphic"}C), but did not increase migration in one cell line ([Supplementary Fig. S2](#f0040){ref-type="graphic"}d). From our results, overexpression of C/EBPδ induces a MET phenotype by suppressing Vimentin and increasing E-cadherin meanwhile decreasing cellular growth, but increasing the migratory effects of cells.

EMT genes such as *Snail*, *Twist,* and the *Zeb* family of transcription factors can change the phenotypical characteristics of cells to regulate this phenomenon. E-cadherin protein expression has been shown to be reduced in some primary ovarian carcinomas, and then re-expressed in ovarian carcinoma effusions and at metastatic sites \[[@bb0290]\]. Further, ovarian carcinoma cells can co-express E-cadherin and the EMT-associated N-cadherin suggesting that ovarian carcinoma cells undergo incomplete EMT \[[@bb0295],[@bb0300]\]. We found similar co-expression of both E-cadherin and Vimentin proteins in benign FTE. Expression of E-cadherin protein goes up in neoplastic STIC lesions while the EMT associated protein, Vimentin is decreased ([Supplementary Fig. S3](#f0045){ref-type="graphic"}a-b). Furthermore, microarray analysis from a previous publication identified the heterogeneous expression of multiple EMT markers in normal fallopian tube epithelia across the luteal and follicular phases ([Supplementary Fig. S3](#f0045){ref-type="graphic"}e). A panel of six HGSC probed for EMT/MET markers using immunoblots demonstrated the variable expression levels of these markers, consistent with other publications ([Supplementary Fig. S5](#f0055){ref-type="graphic"}c). IHC analysis of a STIC and HGSC sample showed that Vimentin and E-cadherin levels were low in HGSC, but E-cadherin protein levels were higher in STIC relative to Vimentin levels ([Supplementary Fig. S3](#f0045){ref-type="graphic"}c-d). Quantitative RT-PCR (qPCR) showed a significant increase in *Snail*, *Twist,* and *Zeb* in FTE-C/EBPδ-OE cells compared to FTE-Ctrl (*p* \< 0.01, n = 3), in the two independent FTE cell lines ([Fig. 5](#f0025){ref-type="fig"}a). In contrast, C/EBPδ protein overexpression resulted in a decrease in protein expression levels of Twist, Slug, Zeb1, Vimentin, and N-cadherin, and an increase of Snail protein compared to control cells ([Fig. 5](#f0025){ref-type="fig"}b) indicating C/EBPδ influences a MET program in normal fallopian tube cells.

3.5. C/EBPδ induces a MET/EMT regulatory phenotype {#s0145}
--------------------------------------------------

It is well established that miRNAs regulate translation efficiency of genes by targeting mRNA \[[@bb0305]\]. This can result in differences between the amount of protein and mRNA in a cell. Certain genes, such as p53, alter the expression of miRNA which results in changes in the phenotypical characteristics of cells. Loss of p53 in mouse ovarian epithelial cells resulted in downregulation of miRNA-34b and miRNA-34c which decreased proliferation and anchorage independent growth \[[@bb0310]\]. C/EBPδ, itself has been shown to be regulated by miRNA regulatory networks with IL6 and TNF \[[@bb0315]\]. To determine whether there were differences in miRNA expression, the miRNA of FTE-C/EBPδ-OE was compared to FTE-Ctrl cells using a miRNA qPCR Array Human Ovarian cancer array (84 miRNAs). Comparisons were made between 19-FTE-C/EBPδ-OE/Ctrl and 57-FTE-C/EBPδ-OE/Ctrl cell lines ([Supplementary Fig. S2](#f0040){ref-type="graphic"}f). There were 10 miRNAs that were commonly differentially expressed across both FTE-C/EBPδ over-expressing cells lines with a \>2-fold change. Of these, let-7b-5p, miR-125b-1-3p, miR-143-3p, miR-145-5p, miR-224-5p and, miR-346 were up-regulated and miR-26a-5p, miR-27a-3p, miR-106-5p, miR-200b-3 were down-regulated ([Fig. 5](#f0025){ref-type="fig"}C, [Supplementary Fig. S2](#f0040){ref-type="graphic"}f). miR-200b was downregulated in cells where C/EBPδ was over-expressed. MiR-200b is downregulated in ovarian cancer and has been known to target Zeb1, Zeb2, and Slug which are repressors of E-cadherin \[[@bb0320],[@bb0325]\]. Low levels of miR-200 in addition to a decrease in E-cadherin results in an increase in Vimentin, N-cadherin, Twist, and Snail \[[@bb0330]\]. Overexpression of let-7b suppresses cancer cell growth \[[@bb0335],[@bb0340]\] and therefore, may be one of the mechanisms by which C/EBPδ controls the fallopian tube epithelial cell cycle. C/EBPδ has also been shown to be involved in miRNA gene networks with IL6 -- miR-26a-5p, TNF - miR-143-3p, and miR-27a, CREBBP -- miR-27b \[[@bb0315]\]. The results suggest a role for C/EBPδ in altering miRNA expression profiles within normal FTE which influences downstream regulatory pathways of the epithelial to mesenchymal transition ([Fig. 6](#f0030){ref-type="fig"}j,k).

3.6. C/EBPδ functions as a regulatory transcriptional factor in epithelial cancer {#s0150}
---------------------------------------------------------------------------------

In vitro, overexpression of C/EBPδ in SKOV3 led to an epithelial phenotype characterized by well-defined cells compared to control cells, which had a more elongated, mesenchymal phenotype ([Fig. 6](#f0030){ref-type="fig"}a, [Supplementary Fig. S4](#f0050){ref-type="graphic"}a). Furthermore, FACS analysis of SKOV3 cells demonstrated an increase in EpCAM^+^ cells and decrease in Cd49f^+^ relative to control ([Supplementary Fig. S4](#f0050){ref-type="graphic"}b). Across FTE cells, EPCAM^+^ cell expansion was noted, consistent with the cancer cell line ([Supplementary Fig. S4](#f0050){ref-type="graphic"}d). Similar to FTE, western blot analysis revealed that overexpression of C/EBPδ in SKOV3 induced E-cadherin and decreased Vimentin, Zeb1, and Zeb2 expression levels ([Fig. 6](#f0030){ref-type="fig"}b) and reduced cell growth ([Fig. 6](#f0030){ref-type="fig"}c). Interestingly, SKOV3 with C/EBPδ overexpression had reduced migration relative to control cells, which could be an effect of its p53 status (24-fold, *p* \< 0.001, n = 3) ([Fig. 6](#f0030){ref-type="fig"}d). In addition, two independent ovarian cancer cell lines (Kuramochi and OVSAHO) with C/EBPδ overexpression showing a small, compact cellular phenotype relative to controls ([Fig. 6](#f0030){ref-type="fig"}e), growth was also reduced ([Fig. 6](#f0030){ref-type="fig"}f). Western Blot analysis showed increased E-cadherin and decreased Vimentin in Kuramochi and OVSAHO cells with C/EBPδ overexpression relative to controls ([Fig. 6](#f0030){ref-type="fig"}g). Kuramochi cells expressing C/EBPδ reduced the formation of anchorage independent growth colonies relative to control experiments (2.5-fold, *p* = 0.02, n = 3) but increased cell migration, however this effect was not observed in OVSAHO cells ([Fig. 6](#f0030){ref-type="fig"}h,i).

We next studied the effect of C/EBPδ overexpression in breast cancer cells lines MCF7 and T47D which have higher overall E-cadherin compared to the more mesenchymal MDA-231 cells. C/EBPδ protein expression levels are highest in MCF7, which is associated with strong expression levels of epithelial markers, E-cadherin and CK8, while MDA-231 has low C/EBPδ expression which is associated with low E-cadherin and CK8 expression and high Vimentin expression ([Supplementary Fig. S6](#f0060){ref-type="graphic"}a). Since C/EBPδ basal protein expression levels were low in proliferating FTE and in HGSC, we used MCF7 cell line where basal levels of C/EBPδ can be clearly detected by western blot analysis to determine if C/EBPδ is necessary to maintain proliferation ([Supplementary Fig. S6](#f0060){ref-type="graphic"}a, b). A non-targeting (NT) control cell line and a C/EBPδ-knockdown (KD) stable cell line were generated in MCF7 ([Supplementary Fig. S6](#f0060){ref-type="graphic"}b). Growth inhibitory effects of C/EBPδ overexpression were observed in cancer cell lines which resulted in reduced cell growth in MCF7, T47D, but an increased growth in MDA-231 compared to controls ([Supplementary Fig. S6](#f0060){ref-type="graphic"}d, h). Proliferation assays demonstrated that in MCF7, C/EBPδ overexpression decreased cell growth at day 3 (3.6-Fold, *p* = 0.01), day 5 (4.7-Fold, *p* = 0.04), day 7 (11.43-Fold, *p* = 0.002), and day 10 (30-Fold, p = 0.002) compared to control cells ([Supplementary Fig. S6](#f0060){ref-type="graphic"}d). Loss of C/EBPδ expression in MCF7 had no significant effect on cell growth (Supplementary Fig. 6d). However, C/EBPδ protein overexpression resulted in a decrease of anchorage independent growth (1.6-fold, p = 0.01) ([Supplementary Fig. S6](#f0060){ref-type="graphic"}f). In contrast, MDA231 with C/EBPδ overexpression resulted in increased soft agar colony formation relative to control cells ([Supplementary Fig. S6](#f0060){ref-type="graphic"}i). A second breast cancer cell line, T47D, overexpressing C/EBPδ demonstrated a signifcant decrease in cell proliferation at day 3 (11.45-Fold, *p* = 0.00009), day 5 (11.67-Fold, *p* = 0.01), and day 10 (12.5-Fold, *p* = 0.01) ([Supplementary Fig. S6](#f0060){ref-type="graphic"}g, h), but in the more mesenchymal cell line, MDA231, C/EBPδ increased growth rates slightly compared to controls, albeit not statistically significant (*p* = 0.35) ([Supplementary Fig. S6](#f0060){ref-type="graphic"}g, h). In the context of MCF7, a hormonally responsive breast cancer cell line, C/EBPδ expression is sufficient to inhibit anoikis by anchorage independent growth.

EMT markers such as Snail and Twist were expressed in T47D cells and Zeb2 was expressed in all three cell lines ([Supplementary Fig. S5](#f0055){ref-type="graphic"}a). In MCF7, overexpression of C/EBPδ resulted in an increase in E-cadherin expression while silencing of C/EBPδ reversed E-cadherin levels ([Supplementary Fig. S6](#f0060){ref-type="graphic"}b). Using T47D cells overexpressing C/EBPδ there was no effect on Snail protein expression and a slight decrease in Twist protein expression ([Supplementary Fig. S5](#f0055){ref-type="graphic"}b). An in-vitro observation of MCF7 cells with overexpression C/EBPδ using bright field microscopy showed cells were more compact and rounded, indicative of an epithelial phenotype, compared to cells with a C/EBPδ knockdown, which displayed filipodia and were less compact ([Supplementary Fig. S6](#f0060){ref-type="graphic"}c). As in FTE, the overexpression of C/EBPδ in MCF7 cells resulted in significantly more cells migrating relative to control cells (1.74 fold, p = 0.004) ([Supplementary Fig. S6](#f0060){ref-type="graphic"}e). Taken together, as normal cells transition toward a neoplastic state, C/EBPδ protein expression decreases resulting in less control over the cell cycle and as a consequence pushes the cell to a more epithelial phenotype (MET) which in the context of high-grade serous cancer makes it more permissive to transformation ([Fig. 6](#f0030){ref-type="fig"}j,k). In many in vitro and in vivo models of EMT, polarized epithelial cells EMT, cells lose polarity, cell-cell adhesion, and acquire migratory and invasive properties \[[@bb0345]\]. In the FTE, a polarized epithelial layer of ciliated and secretory, Cytokeratin 18 (CK18^+^) cells, express both Vimentin and E-cadherin, and undergo a modified mesenchymal to epithelial transition during serous tubal intraepithelial transformation.

4. Discussion {#s0155}
=============

In this study, we present a role for C/EBPδ in the regulation of an EMT/MET program during early preneoplastic changes in the fallopian tube. Expression of C/EBPδ is high in \~40% of STICs and expression from STIC to HGSC is maintained in the 40/60% high-low ratio. High expression of C/EBPδ promotes a partial EMT/MET phenotype in FTE cells. C/EBPδ has a role in promoting cell migration despite decreasing cell proliferation, a characteristic that has been identified in mesenchymal-like breast cancer cells expressing YB-1 \[[@bb0350]\]. It is possible that C/EBPδ reduces proliferation rates thereby decreasing cell density allowing for the monolayer migration \[[@bb0355]\]. In the context of a p53 mutation and C/EBPδ, cells become more mesenchymal relative to baseline, which results in an MET phenotype. This feature, as seen in the luteal phase of the ovarian cycle, results in slower growth. Independent of C/EBPδ, the fallopian tube epithelial cells express a mesenchymal protein, Vimentin, which changes with the ovulatory cycle. This highlights a new appreciation of the inherent epithelial and mesenchymal features of FTE cells which either facilitate or inhibit tumorigenesis ([Fig. 6](#f0030){ref-type="fig"}j,k).

Previously, by comparing hormonally driven changes of phenotypically normal FTE from women with and without a BRCA1 mutation, we identified several differentially expressed genes with known functions that promote tumour development and metastasis \[[@bb0130],[@bb0220]\]. Amongst these genes, C/EBPδ, a transcriptional regulator of cellular differentiation, inflammatory signaling, hypoxia adaptation, and metastatic progression, was increased during the luteal phase of the ovarian cycle \[[@bb0130]\]. C/EBPδ has dualistic roles as a tumour suppressor or oncogene and has been called a master regulator gene. In breast cancer cell line, MCF7, C/EBPδ was shown to decrease CylinD1 by mediating CCND1 degradation through Cdc27/APC3 regulation \[[@bb0360],[@bb0365]\]. In the epidermoid skin cancer cell line, A431, C/EBPδ also decreased cancer cell proliferation induced by interacting with E2F1 and Rb \[[@bb0175]\]. In leukemia, CML, KCL22 and K562 cell lines, expression of C/EBPδ was associated with downregulation of c-Myc and cyclinE1 and upregulation of the cyclin-dependent kinase inhibitor p27 \[[@bb0160]\]. We sought to establish C/EBPδ\'s role in the pathogenesis of high-grade serous ovarian cancer. Our tissue-based data revealed that 77% of a cohort of HGSC cases had low C/EBPδ protein expression compared to LGSCs. This difference may be reflective of the underlying pathogenic routes to these distinct tumours that arise in the fallopian tube \[[@bb0015],[@bb0370]\]. HGSC is fast growing and has a high proliferative index compared to LGSC, which is slow growing and indolent \[[@bb0375]\]. In our cohort of normal FTE and serous intraepithelial carcinoma in situ (STIC) cases, C/EBPδ expression was inversely correlated to Ki67 expression. Higher expression levels of C/EBPδ were associated with lower Ki67 staining and the trend was consistent in HGSCs. This suggests that C/EBPδ is preferentially downregulated in highly proliferative tissues of the fallopian tube and cancer.

Since C/EBPδ expression is higher in the normal tissues compared to 70% of HGSC, we used an in vitro FTE model to explore the effects of C/EBPδ overexpression in p53 dominant negative mutant cells \[[@bb0040]\]. In this study, C/EBPδ overexpression decreased cellular growth resulting in accumulation of the cells in the G1/S phase of the cell cycle. This observation was extended to ovarian and breast cancer cell lines, suggesting C/EBPδ is enough to inhibit growth. Unfortunately, endogenous levels of C/EBPδ were too low to observe an additional decrease in endogenous protein levels in the modeled premalignant fallopian tube cells. However, silencing C/EBPδ in MCF7 did not affect growth, suggesting that C/EBPδ is sufficient but not necessary for proliferation.

Within the normal tissue, C/EBPδ levels are higher in the luteal phase of the menstrual cycle relative to the follicular phase. The luteal phase constitutes a highly inflammatory milieu with fallopian tube epithelial cells undergoing differentiation to accommodate the motility of the ovum toward the ampulla for impregnation. C/EBPδ is rapidly induced by inflammatory signals, cytotoxic factors, and stressful conditions, which are characteristics of the luteal phase \[[@bb0135],[@bb0380]\]. Given that C/EBPδ has a dichotomous role in regulating proliferation and differentiation \[[@bb0160]\], we hypothesized the expression of C/EBPδ might be slowing the growth of cells to prepare them for a transitional state. Indeed, we describe C/EBPδ\'s role for the first time in mediating an EMT/MET switch thereby providing FTE with epithelial plasticity and enabling the migratory potential of these cells. We hypothesize higher levels of C/EBPδ in premalignant FTE might alter cell phenotype toward an epithelial fate with potential to migrate to the ovarian surface epithelium.

One of the main points of debate regarding the fallopian tube epithelial origin of HGSC is how mesenchymal cells of origin (i.e. fallopian tube epithelial cells) form serous epithelial ovarian carcinoma. Factors other than location and proximity contribute to seeding to the ovary by fallopian tube precursor lesions. We hypothesized menstrual cycle associated genes with dual role of controlling proliferation and differentiation might play an important role in this process. In our FTE cell culture model, a p53 dominant negative (R175H) mutation was introduced to recapitulate one of the earliest known events in HGSC, namely, the p53 signature. Loss of p53 was previously shown to induce mesenchymal-like features in normal mammary epithelial cells \[[@bb0320]\]. We report similar findings in FTE. We also observed expression of Twist, Slug, Zeb1, and Zeb2 at the protein level in p53 deficient FTE cells, a feature consistent with a mesenchymal phenotype \[[@bb0385]\].

Here we showed C/EBPδ overexpression induced a partial MET, characterized by an increase in expression of epithelial markers, E-cadherin and CK7, and a decrease in expression of mesenchymal markers, including Vimentin and N-cadherin. This was observed in FTE precursor lesions as well as cancer cell lines. Furthermore, upon C/EBPδ overexpression, a decrease in the expression of Twist, Slug, and Zeb1 were observed at the protein level. The data suggests a role for C/EBPδ in regressing the mesenchymal phenotype of p53 mutated FTE cells. The overexpression of C/EBPδ still increased the migratory rate of FTE cells and cancer cell lines. However, knocking down C/EBPδ in a cancer cell line did not demonstrate a significant difference in migration relative to controls. In urothelial cancers (UC), C/EBPδ enhanced the invasiveness of UC cells through direct binding and upregulation of MMP2 \[[@bb0390]\]. This highlights a dichotomous role of C/EBPδ as a tumour suppressor or oncogene with tumour promoting potentials depending on the tissue and the genomic context within which the gene is expressed. Primary fallopian tube cells have limited growth expansions in vitro \[[@bb0040]\] and therefore, conducting these experiments in the p53 wild type setting was not feasible. However, the presence of p53-R175H mutation along with C/EBPδ over-expression promotes cellular migration.

Human fallopian tube epithelial cells do not require intravasation to metastasize to the ovary and other organs in the abdominal cavity. FTE cells are exposed to the peritoneal cavity where they can slough off easily and disseminate to other locations. This study highlights new roles for C/EBPδ in HGSC and separately features intriguing EMT/MET hybrid FTE phenotypes influenced by the ovulatory cycle. This hybrid-pleiotropic phenotype in cancer is implicated in cancer metastasis, cancer stem cell plasticity, chemoresistance, and immune evasion \[[@bb0395],[@bb0400]\], all features also attributed to ovarian cancer biology and heterogeneity. These EMT/MET protein expressions observed in the histologically normal fallopian tube epithelia and pre-malignant lesions need further study to identify core transcriptional and genomic/epigenomic networks driving fallopian tube epithelia transformation. Further, FTE cells endogenously express well-established mesenchymal markers like Vimentin and epithelial markers as E-cadherin simultaneously which can be considered an intermediate phenotype \[[@bb0265]\]. Acquisition of mutant p53 is not required for these cells to express mesenchymal genes, but may play a role in promoting anoikis and survival in the peritoneal cavity once detached from the basement membrane. During the ovulatory cycle, C/EBPδ decreases cell growth and can influence mesenchymal gene expression potentially through miRNAs. Although the connection between C/EBPδ and miRNA requires further study, several publications have highlighted the role of C/EBPδ in regulating miRNA resulting in downstream phenotypical differences in cells with and without C/EBPδ, as is the case of miR-193b in urothelial human carcinoma\'s which demonstrated and anti-tumourigenic function of C/EBPδ through miR-193b in NUTB1 human urothelial carcinoma cell line \[[@bb0405]\]. In this context, we suggest a model whereby C/EBPδ\'s initial expression in premalignant FTE would slow cell cycle progression and allow these cells to acquire epithelial phenotype with potential to avoid anoikis and migrate to the ovary. Once these cells have migrated to the ovary, decreased expression of C/EBPδ promotes the proliferative potential of the cells which maintain a mesenchymal phenotype reminiscent of the cell of origin. Future studies are warranted to investigate which other genes and/or gene networks promote these MET/EMT switches in early fallopian tube epithelial cells transformation and whether these networks are elicited in chemoresistant ovarian cancer.

The following are the supplementary data related to this article.Supplementary Fig. S1a. C/EBPδ was overexpressed in 57-FTE cells. Overexpression is shown by a brighter GFP signal in the nucleus of cells with C/EBPδ overexpression compared to control cells (white arrows). b. 57-FTE cells expressing C/EBPδ have compact, epithelial like phenotype compared to control cells. c. The migratory potential of 57-FTE and 19-FTE was determined using a wound healing assay. Cells with C/EBPδ overexpression migrated quicker relative to control cells (57-FTE--p53DN-hTERT (2.04-fold, *p* \< 0.01) and 19-FTE--p53DN-hTERT (1.6-fold, *p* \< 0.01)).Supplementary Fig. S1Supplementary Fig. S2a. Western blot analysis of EMT markers 71-FTE. b. Over-expression of C/EBPδ decreased cell growth of 71-FTE similar to other FTE cell lines (Statistical significance derived using paired *t*-test (*p* \< 0.001)). c. Increase in colony formation in this more mesenchymal phenotype FTE-line when C/EBPδ is over-expressed. d. Overexpression of C/EBPδ decreased 71-FTE migration relative to controls. e. C/EBPδ protein quantification in three FTE cell lines. f. miRNA expression between FTE with C/EBPδ and without C/EBPδ was assessed and showed many miRNA differentially expressed between FTE-C/EBPδ-OE and FTE-Ctrl cells. Statistical significance derived using 2-way ANOVA. Statistically significant (*p* \< 0.05) miRNA *p*-values are determined by a Student\'s *t*-test (two tail distribution and equal variances between the two samples).Supplementary Fig. S2Supplementary Fig. S3a. High expression level of E-cadherin (ECAD) and Vimentin (VIM) in normal fallopian tube epithelium. b. Low expression level of E-cadherin and Vimentin in normal fallopian tube epithelium. c. Comparative immunohistochemical image of C/EBPδ, E-cadherin and Vimentin, showing differential expression of each marker between normal fallopian tube epithelia and serous tubal intraepithelial carcinoma. d. Expression level of C/EBPδ, E-cadherin and Vimentin in HGSC. e. Normalized gene expression data derived from microarray analysis of normal fallopian tube cases of the luteal and follicular phases and BRCA mutation carriers of the luteal and follicular phases.Supplementary Fig. S3Supplementary Fig. S4a. C/EBPδ expressed in SKOV3 cells and confirmed by GFP and immunofluorescence. b. FACS analysis of SKOV3 cells show C/EBPδ-OE cells with increased EPCAM and CD49f expression relative to control cells. c. Overexpression of C/EBPδ did not alter Rb levels, but increased EZH2 relative to control cells. d. FACS analysis of three fallopian tube cells show EPCAM and CD49 expression in cells expressing C/EBPδ.Supplementary Fig. S4Supplementary Fig. S5a. Western Blot Images of three breast cancer cell lines (MCF7, T47D, MDA-231) show differential expression of Twist, Snail, Zeb2, p53, and B-actin. b. Additional breast cancer cell lines show western blot protein expression level of C/EBPδ and EMT markers. c. Western blot of six HGSC and expression levels of EMT/MET markers. d. Protein quantification of C/EBPδ across ovarian and breast cancer cell lines.Supplementary Fig. S5Supplementary Fig. S6a. C/EBPδ protein expression was compared in three breast cancer cell lines, MCF7, T47D, MDA231, using western blot analysis. b. Western blot analysis of C/EBPδ, mesenchymal marker N-cadherin, epithelial marker E-cadherin, EMT/MET markers, including Zeb1, Snail, as well as ERα whole-cell lysates in MCF7 control cells, C/EBPδ overexpressing cells and C/EBPδ deficient cells (shC/EBPδ). B-actin is used as a loading control. c. Images of MCF7 cells overexpressing C/EBPδ, C/EBPδ deficient cells (shC/EBPδ) and corresponding controls were taken using bright field light microscope at 10× and 20× magnification. d. Cell growth was measured in MCF7-Ctrl cells, MCF7- C/EBPδ-OE, and MCF7-shC/EBPδ. e. Migration assay of MCF7 cells overexpressing C/EBPδ, C/EBPδ deficient cells (shC/EBPδ) and corresponding controls (n = 3). Data are represented as mean +/− SEM and p-values are calculated using student *t*-tests, two-tailed. f. Anchorage independent growth assay of MCF7 cells overexpressing C/EBPδ. *P*-values derived by using an unpaired t-test (\**p* \< 0.01, n = 3). g. A western blot of T47D and MDA231 cells overexpressing C/EBPδ show protein expression levels of the gene. h. Cell growth curves of T47D and MDA231 show derease in T47D-C/EBPδ-OE relative to control but no difference between MDA231-C/EBPδ-OE and control cells. i. Soft agar assay of MDA231 cells overexpressing C/EBPδ.Supplementary Fig. S6Supplementary Table S1Real-time primers for quantitative PCR analysis.Supplementary Table S1
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